{"id":36131,"date":"2023-08-23T12:23:47","date_gmt":"2023-08-23T10:23:47","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/ipsen-joins-clinical-collaboration-to-evaluate-cabozantinib-cabometyx-plus-atezolizumab-in-metastatic-non-small-cell-lung-cancer-and-metastatic-castration-resistant-prostate-cancer\/"},"modified":"2024-08-09T07:34:43","modified_gmt":"2024-08-09T05:34:43","slug":"ipsen-joins-clinical-collaboration-to-evaluate-cabozantinib-cabometyx-plus-atezolizumab-in-metastatic-non-small-cell-lung-cancer-and-metastatic-castration-resistant-prostate-cancer","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/press-releases\/ipsen-joins-clinical-collaboration-to-evaluate-cabozantinib-cabometyx-plus-atezolizumab-in-metastatic-non-small-cell-lung-cancer-and-metastatic-castration-resistant-prostate-cancer\/","title":{"rendered":"Ipsen joins clinical collaboration to evaluate cabozantinib (CABOMETYX\u00ae) plus atezolizumab in metastatic non-small cell lung cancer and metastatic castration-resistant prostate cancer"},"content":{"rendered":"